HBOT Has Strong Scientific Evidence for Specific Indications
Yes, hyperbaric oxygen therapy (HBOT) has robust scientific evidence supporting its use in specific clinical conditions, most notably carbon monoxide poisoning, where it significantly reduces mortality and prevents delayed neurological sequelae. 1
Established Evidence-Based Indications
Carbon Monoxide Poisoning (Strongest Evidence)
The 2025 Polish Medical Society guidelines provide the most comprehensive and recent evidence for HBOT 1:
HBOT reduces delayed neurological sequelae (DNS) risk by limiting ischemia-reperfusion injury and oxidative CNS damage, with observational studies showing >30% relative reduction in in-hospital mortality when initiated early 1
Critical timing factor: HBOT delay ≥200 minutes increases DNS odds almost 19-fold; optimal initiation is within 3 hours 20 minutes, acceptable up to 6 hours 1
Mandatory indications:
- All pregnant women with CO exposure, regardless of COHb level or symptoms 1
- Persistent neurological or cardiac symptoms despite normobaric oxygen
- Severe metabolic acidosis
- Loss of consciousness or neurological deficits 1
Protocol: 2.2-2.8 ATA for 60-120 minutes; second session within 24 hours if inadequate response 1
Important caveat: Evidence beyond 24 hours post-exposure is not supported; sessions >24 hours lack medical evidence 1
Emerging and Condition-Specific Evidence
Traumatic Brain Injury (Mixed Evidence): A 2026 meta-analysis of 570 patients showed HBOT significantly improved 2:
- Computerized cognitive performance (SMD = 0.23, p = 0.004)
- Executive function and processing speed (SMD = -0.59, p = 0.0005)
- Memory function (SMD = 0.33, p = 0.03)
- Sleep quality (MD = 1.98, p = 0.04)
However, no significant benefits for Glasgow Outcome Scale, PTSD symptoms, or neurobehavioral symptoms 2. Evidence predominantly applies to mild TBI, not moderate-to-severe cases.
Myocardial Injury (Preliminary Evidence): 2026 systematic review of 431 patients showed 3:
- Up to 35% reduction in CPK levels in acute MI (p=0.03)
- Improved left ventricular ejection fraction (p<0.05)
- Reduced postoperative inflammatory markers in cardiac surgery
- Limitation: Studies remain heterogeneous; larger trials needed
Central Retinal Artery Occlusion: 2026 meta-analysis favored HBOT (OR = 0.47; 95% CI: 0.26-0.87; p = 0.02), but only when initiated within 12 hours; delayed treatment showed attenuated benefits 4
Conditions with Insufficient or Negative Evidence
Diabetic Foot Ulcers (Controversial): The 2019 American Diabetes Association guidelines highlight contradictory evidence 5:
- One double-blind study showed significantly more complete healing at 1 year
- However, the Dutch DAMOCLES trial (most recent high-quality study) demonstrated HBOT did NOT significantly improve wound healing or limb salvage in ischemic diabetic wounds 5
- Multiple studies failed to demonstrate benefit or had design flaws
- No significant effect on quality of life 5
Clinical recommendation: HBOT should be a topic of shared decision-making, considered only after standard wound therapy fails for ≥30 consecutive days, per Medicare criteria 5
Osteoradionecrosis: 2024 ISOO-MASCC-ASCO guidelines identified only 11 studies (6 RCTs) on HBOT for ORN management 6. Evidence quality remains limited with substantial heterogeneity.
Mechanism of Action
HBOT works through pharmacological actions beyond simple tissue reoxygenation 7:
- Increased oxygen pressures in blood and tissues
- Specific effects on immunological and metabolic pathways
- Modulation of inflammatory responses
- Enhanced tissue oxygenation in hypoxic/ischemic areas 8, 7
Common Pitfalls to Avoid
- Do not use COHb levels alone to determine HBOT need in CO poisoning - clinical status is primary criterion 1
- Do not delay HBOT beyond 6 hours in indicated cases - efficacy dramatically decreases after 200 minutes 1
- Do not apply TBI evidence to moderate-severe cases - current data predominantly from mild TBI 2
- Do not use HBOT as first-line for diabetic foot ulcers - insufficient evidence; standard wound care first 5
- Always weigh transport risks against benefits - patient stability is paramount 1
Evidence Quality Summary
Strong evidence (Guideline-level): Carbon monoxide poisoning [1-1]
Moderate evidence (Research-level): Mild TBI cognitive outcomes 2, acute myocardial injury 3, early CRAO 4
Weak/Insufficient evidence: Diabetic foot ulcers 5, osteoradionecrosis 6, moderate-severe TBI 2
The evidence base for HBOT is condition-specific and timing-dependent; blanket statements about efficacy are inappropriate without specifying the clinical indication and treatment window.